Neutrolis

Neutrolis, Inc. is a private, clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, founded in 2017. The company is pioneering a new class of rapid-acting, non-immunosuppressive therapies that directly target Neutrophil Extracellular Traps (NETs) — web-like structures implicated in tissue damage and chronic inflammation in autoimmune disease. Its proprietary exDNASE™ platform powers the development of DNASE1L3-based enzyme analogs designed to disassemble pathogenic NETs. The lead asset, NTR-1011, is a first-in-class DNASE1L3 fusion protein optimized for subcutaneous delivery. In April 2026, Neutrolis announced positive Phase 1a results from its LIBERATE-I trial, demonstrating a favorable safety profile, predictable pharmacokinetics, and no immunogenicity. Phase 1b trials in patients with moderate-to-severe systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are planned for mid-2026. The company remains an active, independent entity.